Zobrazeno 1 - 10
of 55
pro vyhledávání: '"B. Bayrou"'
Publikováno v:
Thrombosis Research. 63:311-317
The pharmacokinetic characteristics of a low molecular weight heparin (LMWH) (Cy 222; mean mw: 2500 daltons) are studied in 24 patients with 3 degrees of chronic renal failure (CRF) stage I (creatinine clearance between 50 and 30 ml/mn), stage 2 (cre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161d5027eb0a57cc379bb41eadac9763
https://doi.org/10.1016/0049-3848(91)90134-i
https://doi.org/10.1016/0049-3848(91)90134-i
Publikováno v:
Fundamental & Clinical Pharmacology. 4:17-23
Summary— The pharmacodynamic parameters of a low molecular weight heparin (LMWH, CY 216) and their inter-individual variations were investigated. In a cross over study 100 anti-factor Xa IC U/kg were injected, one week apart, to 12 healthy-voluntee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8df93c1cb8b83af516f5c4b63c3c02a
https://doi.org/10.1111/j.1472-8206.1990.tb01013.x
https://doi.org/10.1111/j.1472-8206.1990.tb01013.x
Autor:
L. Milandre, Irène Juhan-Vague, M.F. Aillaud, G. Lagrange, F. Toulemonde, A. Elias, B. Alonzo, A. Serradimigni, Khalil R, B. Bayrou
Publikováno v:
La Revue de Médecine Interne. 11:95-98
The effectiveness and safety of a very low molecular weight heparin fraction were evaluated in the prevention of deep-vein thrombosis in patients confined to bed due to hemiplegia consecutive to a recent cerebral infarction. CY 222 was administered w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5db8dbb49680391806cf174f41e92f2
https://doi.org/10.1016/s0248-8663(05)80622-8
https://doi.org/10.1016/s0248-8663(05)80622-8
Publikováno v:
Nephrologie. 11(3)
The hemorrhagic risk of an association of fractioned heparin (Fraxiparine) injected intravenously at the dose of 7500 AXaICU or of unfractionned heparin (UFH) injected intravenously at the usual dose used for a priming dose for hemodialysis (3750 +/-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::16b8aa6e8d68fbe49f53c8cb8ca6d598
https://pubmed.ncbi.nlm.nih.gov/2234270
https://pubmed.ncbi.nlm.nih.gov/2234270
Autor:
A, Elias, L, Milandre, G, Lagrange, M F, Aillaud, B, Alonzo, F, Toulemonde, I, Juhan-Vague, R, Khalil, B, Bayrou, A, Serradimigni
Publikováno v:
La Revue de medecine interne. 11(1)
The effectiveness and safety of a very low molecular weight heparin fraction were evaluated in the prevention of deep-vein thrombosis in patients confined to bed due to hemiplegia consecutive to a recent cerebral infarction. CY 222 was administered w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::690d65f633ea22e2a6c11bd1dea47988
https://pubmed.ncbi.nlm.nih.gov/2158140
https://pubmed.ncbi.nlm.nih.gov/2158140
Publikováno v:
Pathophysiology of Haemostasis and Thrombosis. 17:201-205
In a venous thrombosis model in the rat obtained by ligation of the inferior vena cava, the effects of standard heparin and CY 216, a low molecular weight heparin fraction, are compared. At a dosage of less than 2 mg/kg b.w. CY 216 is an effective an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b4908549434d0df7fcb25a64d49241
https://doi.org/10.1159/000215744
https://doi.org/10.1159/000215744
Publikováno v:
Thrombosis Research. 50:335-338
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afc8628c89cca782490c0466ec1c122f
https://doi.org/10.1016/0049-3848(88)90235-6
https://doi.org/10.1016/0049-3848(88)90235-6
Publikováno v:
Blood Purification. 7:301-308
A two-step dose-ranging study was undertaken with CY216 (Fraxiparin®) in 8 patients on 7 sessions each. The different doses were administered each time as a single bolus injection at the start of hemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce520352d466188eda8b7a4a5c754a28
https://doi.org/10.1159/000169605
https://doi.org/10.1159/000169605
Autor:
A. Montanari, Anna Maria Cenci, G. Bianchedi, B. Roussel, Gianni Cappelli, P. Morinière, G. Emiliani, Decenzio Bonucchi, Jens Bahlmann, H. Renaud, J. Dieval, J. Delobel, A. Fournier, B. Bayrou, L Lucchi, Christoph Wanner, Peter C. Farrell, Michael J. Lysaght, John Moran, Walter H. Hörl, Egidio Lusvarghi, P. Pasadakis, Klaus Schindhelm, M. Fusaroli, August Heidland, Giuliano Montagnani, Roland M. Schaefer, M. Briganti, E. Thodis, Jürgen Reitinger, Peter Schollmeyer, Marisa De Palma, V Vargemezis, James M. Hayes
Publikováno v:
Blood Purification. 7:I-V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef54aa97e0f70b6513672c225cf80201
https://doi.org/10.1159/000169603
https://doi.org/10.1159/000169603
Publikováno v:
Blood purification. 7(6)
A two-step dose-ranging study was undertaken with CY216 (Fraxiparin) in 8 patients on 7 sessions each. The different doses were administered each time as a single bolus injection at the start of hemodialysis without heparinized priming nor further ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::65d7abfc2be47c14d469bcb4bf8af81d
https://pubmed.ncbi.nlm.nih.gov/2558691
https://pubmed.ncbi.nlm.nih.gov/2558691